Related references
Note: Only part of the references are listed.Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity
Franciska Stappers et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2020)
HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA)
A. S. De Groot et al.
CLINICAL IMMUNOLOGY (2019)
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial
Raphael Schiffmann et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2019)
Effects of immunomodulation in classic infantile Pompe patients with high antibody titers
E. Poelman et al.
ORPHANET JOURNAL OF RARE DISEASES (2019)
Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I
Arunabha Ghosh et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial
Uma Ramaswami et al.
MOLECULAR GENETICS AND METABOLISM (2019)
Antibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment
S. J. van der Veen et al.
MOLECULAR GENETICS AND METABOLISM (2019)
Review of immune tolerance induction in hemophilia A
S. J. Schep et al.
BLOOD REVIEWS (2018)
Tolerance induction in hemophilia: innovation and accomplishments
Alexandra Sherman et al.
CURRENT OPINION IN HEMATOLOGY (2018)
High Sustained Antibody Titers in Patients with Classic Infantile Pompe Disease Following Immunomodulation at Start of Enzyme Replacement Therapy
Esther Poelman et al.
JOURNAL OF PEDIATRICS (2018)
Risk factors for inhibitor development in severe hemophilia a
Isabella Garagiola et al.
THROMBOSIS RESEARCH (2018)
Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY
Wladimir Mauhin et al.
ORPHANET JOURNAL OF RARE DISEASES (2018)
HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study
Christine L. Kempton et al.
BLOOD ADVANCES (2018)
Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study
Maarten Arends et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease
M. Lenders et al.
JOURNAL OF INTERNAL MEDICINE (2017)
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
Maarten Arends et al.
PLOS ONE (2017)
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease
Malte Lenders et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Non-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models
K. M. Lovgren et al.
HAEMOPHILIA (2016)
The burden of inhibitors in haemophilia patients
Christopher E. Walshl et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): The TRIPOD Statement
Gary S. Collins et al.
ANNALS OF INTERNAL MEDICINE (2015)
Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy
Eveline J. Langereis et al.
MOLECULAR GENETICS AND METABOLISM (2015)
Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease
Carin M. van Gelder et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2015)
Immune tolerance strategies in siblings with infantile Pompe disease - Advantages for a preemptive approach to high-sustained antibody titers
Elizabeth O. Stenger et al.
MOLECULAR GENETICS AND METABOLISM REPORTS (2015)
Risky business of inhibitors: HLA haplotypes, gene polymorphisms, and immune responses
Birgit M. Reipert
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Quantification of Globotriaosylsphingosine in Plasma and Urine of Fabry Patients by Stable Isotope Ultraperformance Liquid Chromatography-Tandem Mass Spectrometry
Henrik Gold et al.
CLINICAL CHEMISTRY (2013)
Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease
Suhrad G. Banugaria et al.
GENETICS IN MEDICINE (2013)
Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience
Deeksha S. Bali et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS (2012)
Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry
Ralf Krueger et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2012)
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
Suhrad G. Banugaria et al.
GENETICS IN MEDICINE (2011)
Multiple imputation by chained equations: what is it and how does it work?
Melissa J. Azur et al.
INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH (2011)
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Satish Kumar Singh
JOURNAL OF PHARMACEUTICAL SCIENCES (2011)
Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies
Chloe Tesmoingt et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease
Bernard Benichou et al.
MOLECULAR GENETICS AND METABOLISM (2009)
Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment
Jinhai Wang et al.
NATURE BIOTECHNOLOGY (2008)
Enzyme replacement in Fabry disease: Pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents
Markus Ries et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A
S. C. Gouw et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
Samantha C. Gouw et al.
BLOOD (2007)
Structure-immunogenicity relationships of therapeutic proteins
S Hermeling et al.
PHARMACEUTICAL RESEARCH (2004)
Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta
GE Linthorst et al.
KIDNEY INTERNATIONAL (2004)
Enzyme replacement therapy in Fabry disease - A randomized controlled trial
R Schiffmann et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
